TargetMol

CH-5137291

Product Code:
 
TAR-T30868
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T30868-5mg5mg£1,010.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30868-50mg50mg£1,982.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30868-100mg100mg£2,560.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
CH-5137291 is a pure AR antagonist with AR nuclear translocation inhibition activity. It suppresses castration and prevents the growth of prostate cancer cells.
CAS:
1043446-39-4
Formula:
C18H14F3N5O3S2
Molecular Weight:
469.46
Purity:
0.98
SMILES:
CC1(C)N(C(=S)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F)c1cccc(n1)S(N)(=O)=O

References

1. Ishikura N, Kawata H, Nishimoto A, Nakamura R, Tsunenari T, Watanabe M, Tachibana K, Shiraishi T, Yoshino H, Honma A, Emura T, Ohta M, Nakagawa T, Houjo T, Corey E, Vessella RL, Aoki Y, Sato H. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells. Int J Oncol. 2015 Apr;46(4):1560-72. doi: 10.3892/ijo.2015.2860. Epub 2015 Jan 30. PubMed PMID: 25634071. 2. Kawata H, Arai S, Nakagawa T, Ishikura N, Nishimoto A, Yoshino H, Shiraishi T, Tachibana K, Nakamura R, Sato H. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291. Prostate. 2011 Sep;71(12):1344-56. doi: 10.1002/pros.21351. Epub 2011 Feb 9. PubMed PMID: 21308717. 3. Yoshino H, Sato H, Shiraishi T, Tachibana K, Emura T, Honma A, Ishikura N, Tsunenari T, Watanabe M, Nishimoto A, Nakamura R, Nakagawa T, Ohta M, Takata N, Furumoto K, Kimura K, Kawata H. Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer. Bioorg Med Chem. 2010 Dec 1;18(23):8150-7. doi: 10.1016/j.bmc.2010.10.023. Epub 2010 Oct 15. PubMed PMID: 21050768. 4. Walker K, Padhiar M. AACR-NCI-EORTC--21st International Symposium. Molecular targets and cancer therapeutics--Part 1. IDrugs. 2010 Jan;13(1):7-9. PubMed PMID: 20024838.